Tracers / [177Lu]Lu-FAPI-2286
[177Lu]Lu-FAPI-2286
Also written as [Lu-177]Lu-FAPI-2286; Lu-177-FAPI-2286
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 9
What it is
- Compound class
- FAP-targeting peptide (DOTA-conjugated FAPI-2286)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 41779297
- Clinical application
- FAP-targeted radioligand therapy in lung adenocarcinoma and sarcoma PMID 41432572
- Theranostic pair
- <a href="/tracers/cu64-fapi2286/">cu64-fapi2286</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 41886137 2026 Curr Treat Options Oncol |
| Manual synthesis | — | SPE | — | >95% | FAPI-2286 MedChemExpress | 41779297 2026 EJNMMI Res [177Lu]Lu-FAPI-2286 synthesis was performed using previously established protocols with minor modifications |
| Manual synthesis | — | SPE | — | — | DOTA-FAP-2286 | 41688618 2026 EJNMMI Res FAPI-46 and FAP-2286 were radiolabeled with 111In and 177Lu at a selected pH for 10 min at 100 °C, then purified with a SepPak cartridge |
| — | — | — | — | — | — | 41432572 2026 Clin Nucl Med |
| — | — | — | — | — | — | 42080808 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41984869 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41941243 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41571431 2026 J Nucl Med |
| — | — | — | — | — | FAP2286-SA | 41177127 2025 Bioorg Chem |
Need this precursor?We can point you to suppliers for [177Lu]Lu-FAPI-2286, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 8 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64. Compound class inferred from precursor name (not stated outright) -- PMID 41779297: 'FAPI-2286 was purchased from MedChemExpress (Monmouth Junction, NJ, USA; catalog HY-147057)'. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.